Skip to main content
Top
Published in: Thrombosis Journal 1/2021

01-12-2021 | Thrombosis | Case report

JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature

Authors: Sevastianos Chatzidavid, Nefeli Giannakopoulou, Panagiotis Theodorou Diamantopoulos, Eleni Gavriilaki, Panagiota Katsiampoura, Eleftheria Lakiotaki, Stratigoula Sakellariou, Nora-Athina Viniou, Georgios Dryllis

Published in: Thrombosis Journal | Issue 1/2021

Login to get access

Abstract

Background

Polycythemia vera (PV) is characterized by red cell mass expansion in the peripheral blood and can be complicated with thrombosis, bleeding, evolution to acute myeloid leukemia (AML) or a fibrotic phase. Paroxysmal nocturnal hemoglobinuria (PNH) in an acquired clonal haematopoietic stem cell disorder associated with chronic intravascular hemolysis, venous thrombosis, defective hematopoiesis, frequent episodes of infection and, rarely, leukemic transformation. Herein, we report an interesting case of a patient with coexistence of PNH clones and a JAK2V617F positive PV, with unusual thromboses without hemolysis.

Case presentation

A 51-year-old woman presented with increased levels of hematocrit, multiple liver, spleen, and left kidney infarctions and ascites; further investigation revealed a JAK2V617F-positive polycythemia vera and the presence of a significant PNH population (more than 90% CD55– CD59– cells among both granulocytes and red blood cells). Interestingly, the patient has experienced severe thrombotic events without any signs or symptoms of hemolysis.

Conclusions

This case raises questions over uncharted aspects of the PNH etiopathogenesis and its potential association with myeloproliferative neoplasms (MPN) and highlights the difficulty of diagnosing and managing patients with more than one potentially thrombophilic conditions, especially with established and severe thromboses.
Literature
1.
go back to reference Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22(4):355–73.PubMed Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22(4):355–73.PubMed
2.
go back to reference Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.PubMedPubMedCentralCrossRef Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.PubMedPubMedCentralCrossRef
3.
4.
go back to reference Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81.
5.
go back to reference Meletis J, Terpos E, Samarkos M, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. Haematologia (Budap). 2001;31(1):7–16.CrossRef Meletis J, Terpos E, Samarkos M, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. Haematologia (Budap). 2001;31(1):7–16.CrossRef
8.
go back to reference Meletis J, Terpos E, Samarkos M, Meletis C, Apostolidou E, Komninaka V, Korovesis K, Mavrogianni D, Boutsis D, Variami E, Viniou N, Konstantopoulos K, Loukopoulos D. Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes. Hematol J. 2001;2(1):33–7.PubMedCrossRef Meletis J, Terpos E, Samarkos M, Meletis C, Apostolidou E, Komninaka V, Korovesis K, Mavrogianni D, Boutsis D, Variami E, Viniou N, Konstantopoulos K, Loukopoulos D. Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes. Hematol J. 2001;2(1):33–7.PubMedCrossRef
9.
go back to reference Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997;78:617.PubMedCrossRef Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997;78:617.PubMedCrossRef
10.
go back to reference Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients. Mayo Clin Proc. 2008;83(4):457–9. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients. Mayo Clin Proc. 2008;83(4):457–9.
11.
go back to reference Ugo V, Le Gal G, Lecucq L, et al. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost. 2008;6:203.PubMedCrossRef Ugo V, Le Gal G, Lecucq L, et al. Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism. J Thromb Haemost. 2008;6:203.PubMedCrossRef
12.
go back to reference Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113:5617.PubMedCrossRef Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113:5617.PubMedCrossRef
13.
go back to reference De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411.PubMedCrossRef De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411.PubMedCrossRef
14.
go back to reference Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063.PubMedCrossRef Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063.PubMedCrossRef
15.
go back to reference Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state. Q J Med. 1990;76:981.PubMed Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state. Q J Med. 1990;76:981.PubMed
16.
go back to reference Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921.PubMedCrossRef Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921.PubMedCrossRef
17.
go back to reference Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.PubMedCrossRef Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.PubMedCrossRef
18.
go back to reference Kokoris SI, Gavriilaki E, Miari A, Travlou Α, Kyriakou E, Anagnostopoulos A, Grouzi E. Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. Hematology. 2018;23(8):558–66.PubMedCrossRef Kokoris SI, Gavriilaki E, Miari A, Travlou Α, Kyriakou E, Anagnostopoulos A, Grouzi E. Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. Hematology. 2018;23(8):558–66.PubMedCrossRef
20.
go back to reference Acharya J, Westwood NB, Sawyer BM, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol. 1995;55(5):315–21.PubMedCrossRef Acharya J, Westwood NB, Sawyer BM, et al. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol. 1995;55(5):315–21.PubMedCrossRef
22.
go back to reference Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130(7):2031–8.PubMedCrossRef Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130(7):2031–8.PubMedCrossRef
23.
go back to reference Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006;108(9):3223–4.PubMedCrossRef Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006;108(9):3223–4.PubMedCrossRef
24.
go back to reference Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost. 2012;10(1):1–10.PubMedCrossRef Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost. 2012;10(1):1–10.PubMedCrossRef
25.
go back to reference L’Acqua C, Hod E. New perspectives on the thrombotic complications of haemolysis. Br J Haematol. 2015;168(2):175–85.PubMedCrossRef L’Acqua C, Hod E. New perspectives on the thrombotic complications of haemolysis. Br J Haematol. 2015;168(2):175–85.PubMedCrossRef
27.
go back to reference Fowkes FJI, Price JF, Fowkes FGR. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25(1):1–5.PubMedCrossRef Fowkes FJI, Price JF, Fowkes FGR. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25(1):1–5.PubMedCrossRef
28.
go back to reference Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587–91.PubMedCrossRef Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587–91.PubMedCrossRef
29.
go back to reference Jin JY, Tooze JA, Marsh JCW, Gordon-Smith EC. Glycosylphosphatidyl-inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. Br Soc Haematol. 1997;96(3):493–6.CrossRef Jin JY, Tooze JA, Marsh JCW, Gordon-Smith EC. Glycosylphosphatidyl-inositol (GPI)-linked protein deficiency on the platelets of patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria: two distinct patterns correlating with expression on neutrophils. Br Soc Haematol. 1997;96(3):493–6.CrossRef
31.
go back to reference Hansen NE, Killmann SA. Paroxysmal nocturnal hemoglobinuria in myelofibrosis. Blood. 1970;36:428–31.PubMedCrossRef Hansen NE, Killmann SA. Paroxysmal nocturnal hemoglobinuria in myelofibrosis. Blood. 1970;36:428–31.PubMedCrossRef
32.
go back to reference Luzzatto L, Familusi JB, Williams CK, Junaid TA, Rotoli B, Alfinito F. The PNH abnormality in myeloproliferative disorders: association of PNH and acute erythremic myelosis in two children. Haematologica. 1979;64:13–30.PubMed Luzzatto L, Familusi JB, Williams CK, Junaid TA, Rotoli B, Alfinito F. The PNH abnormality in myeloproliferative disorders: association of PNH and acute erythremic myelosis in two children. Haematologica. 1979;64:13–30.PubMed
33.
go back to reference Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253.PubMedCrossRef Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253.PubMedCrossRef
34.
go back to reference Hirai H, Asahara A, Suzuki R. A case of myelofibrosis with paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki. 1973;14:805–11.PubMed Hirai H, Asahara A, Suzuki R. A case of myelofibrosis with paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki. 1973;14:805–11.PubMed
35.
go back to reference Graham DL, Gastineau DA. Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy. Am J Med. 1992;93:671–4.PubMedCrossRef Graham DL, Gastineau DA. Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy. Am J Med. 1992;93:671–4.PubMedCrossRef
36.
go back to reference Nakahata J, Takahashi M, Fuse I, et al. Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia. Leuk Lymphoma. 1993;12:137–42.PubMedCrossRef Nakahata J, Takahashi M, Fuse I, et al. Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia. Leuk Lymphoma. 1993;12:137–42.PubMedCrossRef
37.
go back to reference Boyd AW, Parkin JD, Castaldi PA. A case of paroxysmal nocturnal hemoglobinuria terminating in a myeloproliferative syndrome. Aust N Z J Med. 1970;9:181183. Boyd AW, Parkin JD, Castaldi PA. A case of paroxysmal nocturnal hemoglobinuria terminating in a myeloproliferative syndrome. Aust N Z J Med. 1970;9:181183.
38.
go back to reference Catovsky D, Lewis SM, Sherman D. Erythrocyte sensitivity to in vitro lysis in leukaemia. Br J Haematol. 1971;31:541–50.CrossRef Catovsky D, Lewis SM, Sherman D. Erythrocyte sensitivity to in vitro lysis in leukaemia. Br J Haematol. 1971;31:541–50.CrossRef
39.
40.
go back to reference Fraiman YS, Cuka N, Batista D, Vuica-Ross M, Moliterno AR. Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm. J Blood Med. 2016;7:107–10.PubMedPubMedCentral Fraiman YS, Cuka N, Batista D, Vuica-Ross M, Moliterno AR. Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm. J Blood Med. 2016;7:107–10.PubMedPubMedCentral
41.
go back to reference Tominaga R, Katagiri T, Kataoka K, et al. Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell. Leukemia. 2016;30:1208–10.PubMedCrossRef Tominaga R, Katagiri T, Kataoka K, et al. Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell. Leukemia. 2016;30:1208–10.PubMedCrossRef
42.
go back to reference Gutwein O, Englander Y, Herzog-Tzarfati K, Filipovich-Rimon T, Apel A, Marcus R, Rahimi-Levene N, Koren-Michowitz M. Prevalence of paroxysmal nocturnal hemoglobinuria clones in myeloproliferative neoplasm patients: a cross-sectional study. Clin Lymphoma Myeloma Leuk. 2019;19(12):812–4.PubMedCrossRef Gutwein O, Englander Y, Herzog-Tzarfati K, Filipovich-Rimon T, Apel A, Marcus R, Rahimi-Levene N, Koren-Michowitz M. Prevalence of paroxysmal nocturnal hemoglobinuria clones in myeloproliferative neoplasm patients: a cross-sectional study. Clin Lymphoma Myeloma Leuk. 2019;19(12):812–4.PubMedCrossRef
43.
go back to reference Kuo C-Y, Van Voolen GA, Morrison AN. Primary and secondary myelofibrosis: its relationship to “PNH-like” defect. Blood. 1972;40(6):875–80.PubMedCrossRef Kuo C-Y, Van Voolen GA, Morrison AN. Primary and secondary myelofibrosis: its relationship to “PNH-like” defect. Blood. 1972;40(6):875–80.PubMedCrossRef
44.
go back to reference de Latour RR, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–106.PubMedCrossRef de Latour RR, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–106.PubMedCrossRef
45.
go back to reference Shen W, Clemente MJ, Hosono N, Yoshida K, Przychodzen B, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014;124:4529–38.PubMedPubMedCentralCrossRef Shen W, Clemente MJ, Hosono N, Yoshida K, Przychodzen B, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014;124:4529–38.PubMedPubMedCentralCrossRef
46.
go back to reference Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.PubMedCrossRef Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.PubMedCrossRef
47.
go back to reference Jones C, Levy Y, Tong AW. Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. BMJ Case Rep. 2014;2014:bcr2014205663 Published 2014 Dec 1.PubMedPubMedCentralCrossRef Jones C, Levy Y, Tong AW. Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. BMJ Case Rep. 2014;2014:bcr2014205663 Published 2014 Dec 1.PubMedPubMedCentralCrossRef
48.
go back to reference Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2012;78:211–30. Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2012;78:211–30.
49.
go back to reference Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the highsensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B Clin Cytom. 2012;82:195–208.PubMedCrossRef Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the highsensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B Clin Cytom. 2012;82:195–208.PubMedCrossRef
50.
go back to reference Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–96.PubMedCrossRef Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–96.PubMedCrossRef
51.
go back to reference Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2009;84(10):699.PubMedCrossRef Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2009;84(10):699.PubMedCrossRef
Metadata
Title
JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature
Authors
Sevastianos Chatzidavid
Nefeli Giannakopoulou
Panagiotis Theodorou Diamantopoulos
Eleni Gavriilaki
Panagiota Katsiampoura
Eleftheria Lakiotaki
Stratigoula Sakellariou
Nora-Athina Viniou
Georgios Dryllis
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2021
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-021-00269-8

Other articles of this Issue 1/2021

Thrombosis Journal 1/2021 Go to the issue